Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease

  • Liang-Hao Guo
  • Panagiotis Alexopoulos
  • Robert Perneczky
Original Paper

DOI: 10.1007/s00406-013-0405-4

Cite this article as:
Guo, LH., Alexopoulos, P. & Perneczky, R. Eur Arch Psychiatry Clin Neurosci (2013) 263: 553. doi:10.1007/s00406-013-0405-4


The main objective of the study was to validate the findings of previous cerebrospinal fluid (CSF) proteomic studies for the differentiation between Alzheimer’s disease (AD) dementia and physiological ageing. The most consistently significant proteins in the separation between AD dementia versus normal controls using CSF proteomics were identified in the literature. The classification performance of the four pre-selected proteins was explored in 92 controls, 149 patients with mild cognitive impairment (MCI), and 69 patients with AD dementia. Heart-type fatty acid binding protein (hFABP) and vascular endothelial growth factor (VEGF) CSF concentrations distinguished between healthy controls and patients with AD dementia with a sensitivity and specificity of 57 and 35 %, and 76 and 84 %, respectively. The optimal classification was achieved by a combination of the two additional CSF biomarker candidates in conjunction with the three established markers Amyloid-β (Aβ)1–42, total-Tau (tTau), and phosphorylated-Tau (pTau)181, which resulted in a sensitivity of 83 % and a specificity of 86 %. hFABP also predicted the progression from MCI to AD dementia. The present study provides evidence in support of hFABP and VEGF in CSF as AD biomarker candidates to be used in combination with the established markers Aβ1–42, tTau, and pTau181.


Alzheimer’s disease Biomarker Cerebrospinal fluid Diagnosis Proteomics 

Supplementary material

406_2013_405_MOESM1_ESM.doc (162 kb)
Supplementary material 1 (DOC 162 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Liang-Hao Guo
    • 1
  • Panagiotis Alexopoulos
    • 1
  • Robert Perneczky
    • 1
    • 2
    • 3
  1. 1.Department of Psychiatry and PsychotherapyTechnische Universität MünchenMunichGermany
  2. 2.Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of MedicineThe Imperial College of Science, Technology and MedicineLondonUK
  3. 3.West London Cognitive Disorders Treatment and Research UnitWest London Mental Health TrustLondonUK

Personalised recommendations